China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

SSSE:600062
15.32
CNY
-0.04
(-0.26%)
1.55EPS
10.69P/E
16.87BMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.3
4.94
4.93
5.27
6.16
7.88
8.99
8.15
8.73
9.3
11.04
10.91
10.65
10.45
Basic EPS, GAAP
1.06
0.71
0.63
0.68
0.81
0.93
1.01
0.96
0.9
1.14
1.63
1.58
1.59
1.52
Free Cash Flow per Basic Share
0.4
0.73
0.51
0.63
0.99
1.19
1.15
0.97
0.81
0.86
1.22
1.16
0.84
- -
Dividend per Share
0.26
0.64
- -
0.18
0.19
0.09
0.29
0.31
0.29
0.77
0.3
1.44
0.69
0.56
Book Value per Share
6.48
7.47
5.85
6.41
7.15
7.51
8.25
8.89
9.49
10.12
11.75
10.02
11.2
12.01
Tangible Book Value per Share
5.88
6.82
4.54
5.04
5.12
5.22
5.87
6.55
6.92
6.9
8.41
6.79
7.72
8.58
Basic Weighted Avg Shares
823
1,043
1,043
1,043
1,043
1,043
1,043
1,043
1,043
1,036
1,024
1,028
1,033
1,032
Sales/Revenue/Turnover
6,835
5,153
5,138
5,495
6,422
8,225
9,381
8,504
9,112
9,625
11,310
11,212
11,001
10,784
Operating Margin (%)
11.67
16.09
14.5
15.61
16.75
14.34
13.91
14.55
12.11
13.84
15.92
15.08
16.3
14.5
Depreciation Expense
268
268
270
315
337
345
360
374
467
562
690
756
788
- -
Net Income, GAAP
871
737
661
714
843
969
1,055
1,005
936
1,180
1,670
1,628
1,647
1,568
Effective Tax Rate (%)
18.12
16.15
17.59
18.48
16.3
16.44
15.48
16.59
13.29
14.03
14.08
11.57
11.91
11.69
Profit Margin (%)
12.74
14.29
12.87
13
13.12
11.78
11.25
11.82
10.27
12.26
14.77
14.52
14.97
14.54
Working Capital
2,802
3,286
2,655
3,291
3,571
3,007
3,697
4,133
4,792
4,556
4,602
3,474
4,085
5,457
LT Debt
- -
1
11
- -
2
7
1
122
35
233
30
1,112
1,051
1,759
Total Equity
5,336
6,179
6,434
7,038
7,849
7,909
8,677
9,358
10,477
11,325
12,899
11,112
12,500
13,364
Return on Invested Capital (%)
15.95
11.88
9.88
10.15
11.86
12.45
12.64
11.17
9.77
10.99
12.96
12.67
12.52
- -
Return on Capital (%)
16.81
12.6
10.47
10.23
10.79
12.05
12.57
10.97
9.08
10.26
13.63
12.69
12.61
- -
Return on Common Equity (%)
17.44
12.83
10.78
11.17
11.92
12.66
12.83
11.24
9.76
11.53
14.67
14.39
14.94
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
126
166
136
LT Borrowings
1,542
1,011
1,736
LT Finance Leases
20
22
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,039
1,039
1,039
Market Capitalization
19,286
16,659
16,866

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,053
8,145
9,028
Cash, Cash Equivalents & STI
3,071
2,774
2,120
Accounts Receivable, Net
2,415
2,547
2,427
Inventories
1,496
1,538
1,612
Total Current Liabilities
3,011
3,764
3,571
Payables & Accruals
- -
- -
- -
ST Debt
126
166
136
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.18%
6.52%
12.5%
Free Cash Flow
7.87%
-0.55%
-26.75%
Net Income, GAAP
10.46%
11.88%
1.18%
Sales/Revenue/Turnover
8.41%
5.51%
-1.88%
Total Cash Common Dividend
602.03%
85.98%
-51.59%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,145
3,094
2,619
2,663
11,212
2025
3,079
2,663
- -
2,718
11,001
2026
2,807
2,809
2,451
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.5
0.61
0.34
0.22
1.58
2025
0.49
0.45
- -
0.29
1.59
2026
0.47
0.45
0.31
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.98
0.98
0.26
0.2
1.44
2025
0.01
0.2
- -
0.11
0.69
2026
0.01
0.06
0.38
- -
- -

Company Description

CEO
Qian Zhao
Full Time Employees
13,184
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 1, Lize East 2nd Road Beijing BE China 100102
IPO Date
May 22, 1997
Website
dcpc.com
Business
China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SS) is a leading China-based pharmaceutical company primarily engaged in the research, development, production, and sale of innovative chemical drugs and formulations; its core businesses span three key segments including chronic disease medications for blood pressure, lipid, and glucose control such as compound reserpine amphoteridine tablets (No. 0), gliquinone tablets, amlodipine benzenesulfonate tablets (diazepine), valsartan capsules (Hoetsu), valsartan hydrochlorothiazide tablets (fujiyue), irbesartan dispersible tablets, nifedipine sustained-release tablets (II) (beciline), and nifedipine controlled-release tablets (betsicon); specialist drugs targeting cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia, and respiratory areas; and infusion products encompassing basic infusion, therapeutic infusion, and nutritional infusions like citicoline sodium tablets (Novartis); the company also produces active pharmaceutical ingredients (APIs) and pharmaceutical equipment. Founded in 1939 and headquartered at No. 1, Lize East 2nd Road, Beijing, China, it operates 24 subsidiaries with approximately 13,414 employees, serving primarily the domestic market across major therapeutic categories such as anti-influenza, antihypertensives, antibiotics, oncology, anti-infection, and more, while maintaining strong channel coverage, cost control, and internationalization capabilities as a subsidiary of Beijing Pharmaceutical Group Co., Ltd. In recent developments, the company completed the acquisition of 100% stake in China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group for CNY 3.1 billion in March 2024, consolidating its chemical drugs business and enhancing synergies; it reported 2024 revenue of RMB 11.21 billion and net profit of RMB 1.65 billion, reflecting robust growth in its formulation, chronic disease, specialty, and infusion segments; additionally, it continues to invest over 10% of annual revenue in R&D, supporting new drug innovation and market expansion.